Charles River Laboratories International Inc. stock outperforms competitors on strong trading day
This was the stock's second consecutive day of gains.
Charles River price target lowered to $184 from $220 at Morgan Stanley
Morgan Stanley analyst Tejas Savant lowered the firm’s price target on Charles River (CRL) to $184 from $220 and keeps an Equal Weight rating ...
FierceBiotech1d
Charles River to shutter North Carolina pathology site, lay off up to 31 employees
Charles River is shuttering its pathology facility in Durham, North Carolina, after determining the site “is not a strategic ...
Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors
Shares of Charles River Laboratories International Inc. CRL shed 1.91% to $161.62 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX ...
ENDPOINTS NEWS2d
Charles Riv­er to shut down North Car­oli­na pathol­o­gy fa­cil­i­ty, says it's not a 's­trate­gic fit'
Charles River Laboratories is permanently closing its pathology facility in Durham, NC, after determining it is no longer “a ...
Charles River Labs (CRL) Receives a Hold from J.P. Morgan
In a report released on February 1, Casey Woodring from J.P. Morgan maintained a Hold rating on Charles River Labs (CRL – Research Report), ...
Charles River Laboratories: Retained Earnings, ROE, And Debt Management Will Shape Its Future Amid Weak Demand
Read here for an analysis of Charles River's (CRL) strong financial performance with high ROE and decreasing liabilities, indicating future capital deployment.